Overview

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Status:
NOT_YET_RECRUITING
Trial end date:
2031-01-22
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
Phase:
PHASE3
Details
Lead Sponsor:
Insmed Incorporated